Beta Drugs (NSE:BETA) Cyclically Adjusted FCF per Share: ₹1.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
94 GF Score
Price ₹2,229.10
GF Value ₹1,982.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Beta Drugs Cyclically Adjusted FCF per Share?

Beta Drugs NSE:BETA -1.40% 94 Cyclically Adjusted FCF per Share is ₹1.63 as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 94/100 and a GF Value™ of ₹1,982.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Beta Drugs's adjusted free cash flow per share data for the fiscal year that ended in Mar. 2026 was ₹-15.975. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₹1.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beta Drugs's average Cyclically Adjusted FCF Growth Rate was -38.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 446.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Beta Drugs was 446.30% per year. The lowest was 446.30% per year. And the median was 446.30% per year.

As of today (2026-07-18), Beta Drugs's current stock price is ₹ 2229.10. Beta Drugs's Cyclically Adjusted FCF per Share for the fiscal year that ended in Mar. 2026 was ₹1.63. Beta Drugs's Cyclically Adjusted Price-to-FCF of today is 1,367.55.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Beta Drugs was 1452.02. The lowest was 637.12. And the median was 709.85.


Beta Drugs  (NSE:BETA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Beta Drugs's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2229.10/1.63
=1,367.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Beta Drugs was 1452.02. The lowest was 637.12. And the median was 709.85.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Beta Drugs Cyclically Adjusted FCF per Share Related Terms


Beta Drugs Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Cyclically Adjusted FCF per Share Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 0.01 1.88 2.64 1.63

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.64 0.00 0.00 1.63

NSE:BETA vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beta Drugs Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Cyclically Adjusted Price-to-FCF falls into.


NSE:BETA
94GF Score
Beta Drugs Ltd NSE:BETA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beta Drugs's adjusted Free Cash Flow per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-15.975/164.2724*164.2724
=-15.975

Current CPI (Mar. 2026) = 164.2724.

Beta Drugs Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201703 2.984 105.196 4.660
201803 9.718 109.786 14.541
201903 -22.517 118.202 -31.293
202003 -6.820 124.705 -8.984
202103 12.725 131.771 15.864
202203 10.105 138.822 11.958
202303 5.122 146.865 5.729
202403 19.135 153.035 20.540
202503 -0.679 157.552 -0.708
202603 -15.975 164.272 -15.975

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ₹1.63 mean?
Beta Drugs (NSE:BETA) has a Cyclically Adjusted FCF per Share of ₹1.63 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Cyclically Adjusted FCF per Share too high?
Beta Drugs' current Cyclically Adjusted FCF per Share is ₹1.63. Overall, Beta Drugs has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Beta Drugs' Cyclically Adjusted FCF per Share of ₹1.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Beta Drugs and its competitors. Beta Drugs's current Cyclically Adjusted FCF per Share is ₹1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,982.44, compared to a current price of ₹2,229.10 — trading 12.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ₹1.63. Beta Drugs' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Cyclically Adjusted FCF per Share is ₹1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,229.10 is trading 12.4% above its estimated GF Value™ of ₹1,982.44. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • Cyclically Adjusted FCF per Share: ₹1.63
  • GF Value™: ₹1,982.44 vs. price of ₹2,229.10 (12.4% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
94GF Score

Get the complete analysis for NSE:BETA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,229.10
Price
₹1,982.44
GF Value